Guidelines on long-acting injectable cabotegravir for HIV prevention

Guidelines on long-acting injectable cabotegravir for HIV prevention

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at red...

Full description

Bibliographic Details
Main Author: World Health Organization (author)
Corporate Author: World Health Organization, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Geneva : World Health Organization 2022.
Edition:1st ed
Subjects:
HIV infections > Prevention.
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009719838106719
Table of Contents:
  • Acknowledgements V
  • Abbreviations and acronyms vii
  • Definitions of key terms viii
  • Executive summary IX
  • Purpose ix
  • Guideline development methodology ix
  • New recommendation X
  • Implications for implementation X
  • 1. Introduction 1
  • 1.1 Background 1
  • 1.2 Objective and intended audience 2
  • 1.3 Guiding principles 3
  • 2. Methods for guideline development 4
  • 3. Rationale and supporting evidence 5
  • 3.1 Summary of review findings 5
  • 3.2 Cost-eflectiveness 8
  • 3.3 Values and preferences 9
  • 3.4 Feasibility 10
  • 3.5 Equity 10
  • 3.6 Rationale or recommendation 10
  • 4. Implementation considerations 12
  • 4.1 HIV testing and other testing requirements 12
  • 4.2 Service delivery 14
  • 4.3 Comprehensive services IS
  • 4.4 Offering a choice of PrEP options 15
  • 4.5 Involving communities 15
  • 4.6 Creating awareness and demand 15
  • 4.7 Adherence support and discontinuation 16
  • 4.8 Training and support for providers 16
  • 5. Research gaps and needs '7
  • 5.1 Providing CAB-LA for key populations 17
  • 5.2 CAB-LA for adolescents under age 18 17
  • 5.3 Safety in pregnancy and breastfeeding 18
  • 5.4 Optimal HIV testing strategies and drug resistance 18
  • 5.5 Service delivery models •9
  • 5.6 Population-level impact and costs and cost-effectiveness 20
  • 6. Updating and dissemination 21
  • References 11
  • Annex. Process for developing the guidelines 25
  • Web Annexes
  • Web Annex A. Declarations of interest for the Guideline Development Group and external peer reviewers
  • Web Annex B. Systematic review, meta-analysis and GRADE evidence profile on safety, efficacy, and effectiveness of long-acting injectable cabotegravir (CAB-LA) as pte-exposurt prophylaxis (PrEP) to reduce the risk of HIV acquisition
  • Web Annex C. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis, including long-acting injectable cabotegravir. to prevent HIV infection
  • Web Annex D. Projected population impact of expanding PrEP coverage by offering long-acting injectable PrEP in different settings: model comparison analysis
  • Web Annex E. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
  • Web Annex F. Perspectives and preferences regarding long-acting injectable cabotegravir for HIV prevention among pre-exposure prophylaxis (PrEP) providers: a global survey and in-depth interviews
  • Web Annex G. Evidence-to-decision making table.

Similar Items